转自：中国证券报·中证网 中证报中证网讯（记者 李梦扬）2月24日，云顶新耀公告，公司于当日以线上虚拟会议形式举行的股东 特别大会顺利召开，会议所提呈的全部决议案均获股东正式通过。 记者获悉，本次股东特别大会批准、确认及追认了公司于2025年12月11日与海森生物医药有限公司（简 称"海森生物"）签署的商业化服务协议及其项下拟进行的相关交易，为公司后续商业化运营及业务推进 提供支持。与此同时，大会还批准了向公司管理层授出奖励安排，以及采纳2026年股份计划及相关授权 限额等决议案。 据了解，公司全资附属公司云顶新耀医药科技有限公司（简称"云顶新耀医药科技"）已与海森生物签署 两项战略合作协议，包括商业化服务协议以及授权许可协议。根据商业化服务协议，云顶新耀医药科技 将依托现有的销售与市场体系，为海森生物旗下六款成熟产品提供商业化服务。根据授权许可协议，云 顶新耀医药科技获得在大中华区开展莱达西贝普（Lerodalcibep）的后续临床开发、注册和商业化的独 家许可。商业化服务协议预计将于2026年上半年完成交割（以常规交割条件为准），授权许可协议将立 即生效。 云顶新耀此前表示，公司与海森生物的合作有助于进一 ...

Core Insights - CloudTop New Horizon Limited has signed two strategic cooperation agreements with Haisen Biopharmaceutical Co., Ltd, which will enhance operational efficiency and accelerate commercialization capabilities in the cardiovascular disease sector [2][3] Group 1: Strategic Agreements - The commercial service agreement allows CloudTop New Horizon to provide commercialization services for six mature products from Haisen Biopharmaceutical, with service fees ranging from 20% to 55% of quarterly net sales [3] - The annual transaction cap for Haisen Biopharmaceutical is set at CNY 560 million for 2026, CNY 616 million for 2027, and CNY 677 million for 2028 [3] Group 2: Licensing Agreement - The licensing agreement grants CloudTop New Horizon exclusive rights for the clinical development, registration, and commercialization of Lerodalcibep in Greater China, with an initial payment of approximately CNY 205 million [4] - Potential milestone payments could reach up to CNY 2.12 billion for development and regulatory milestones, and CNY 19.77 billion for sales milestones, along with royalties based on net sales [4] Group 3: Product Development and Market Position - CloudTop New Horizon has established a commercial platform focused on high-potential markets, with its flagship product, Naisukang, achieving sales exceeding CNY 1 billion by Q3 2025, prompting an upward revision of revenue expectations [5] - The next major product, Aiqumote, is expected to be approved for market launch in the first half of 2026, contributing to the company's profitability [5] - Recent strategic moves include increasing stakes in XinQiao Biotech and introducing VIS-101, indicating a focus on expanding into new therapeutic areas [5]